Company profile: Alentis Therapeutics
1.1 - Company Overview
Company description
- Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
Products and services
- ALE.C04: Clinical-stage monoclonal antibody for CLDN1+ cancers engineered to selectively kill tumor cells and open the collagen barrier, enabling immunotherapies and immune system attack
- ALE.P02: Preclinical antibody-drug conjugate for Claudin-1 positive cancer indications engineered to deliver a tubulin inhibitor directly into tumor cells
- Lixudebart: Anti-fibrotic monoclonal antibody for liver, kidney, and lung fibrosis that reverses fibrosis by blocking fibrotic signaling and opening the collagen barrier to preserve or restore organ function
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alentis Therapeutics
Vaccinogen
HQ: United States
Website
- Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinogen company profile →
Frame Therapeutics
HQ: The Netherlands
Website
- Description: Provider of DNA-based cancer vaccines tailored to the unique characteristics of each patient's tumor, aiming to transform cancer treatment by directing the immune system toward Frame neoantigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Frame Therapeutics company profile →
Bird Rock Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of novel biologic therapeutics and immuno-inflammatory regulators, focused on meeting the medical and commercial needs of China’s patients and healthcare system with potential global impact, including RYI-008, an extremely potent monoclonal antibody highly selective to IL-6.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bird Rock Bio company profile →
Opexa Therapeutics
HQ: United States
Website
- Description: Provider of patient-specific immunotherapies for the treatment of multiple sclerosis; its lead candidate, Tcelna, is a personalized T-cell immunotherapy in Phase IIb clinical development (the Abili-T trial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Opexa Therapeutics company profile →
Tmunity Therapeutics
HQ: United States
Website
- Description: Provider of engineered T cell therapies and platforms, developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms to unleash the immunological potential of T cells, treat a wide range of disease indications, and enable control over T cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tmunity Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alentis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alentis Therapeutics
2.2 - Growth funds investing in similar companies to Alentis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alentis Therapeutics
4.2 - Public trading comparable groups for Alentis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →